Abstract
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
MeSH terms
-
Abciximab
-
Angina, Unstable / drug therapy*
-
Antibodies, Monoclonal / therapeutic use
-
Drug Therapy, Combination
-
Eptifibatide
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use*
-
Heparin / therapeutic use
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use
-
Myocardial Infarction / drug therapy*
-
Peptides / therapeutic use
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Tirofiban
-
Tyrosine / analogs & derivatives
-
Tyrosine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Fibrinolytic Agents
-
Immunoglobulin Fab Fragments
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tyrosine
-
Heparin
-
Tirofiban
-
Eptifibatide
-
Abciximab